Logo image of PHAR

PHARMING GROUP NV - ADR (PHAR) Stock Fundamental Analysis

NASDAQ:PHAR - Nasdaq - US71716E1055 - ADR - Currency: USD

8.86  -0.09 (-1.01%)

Fundamental Rating

4

Taking everything into account, PHAR scores 4 out of 10 in our fundamental rating. PHAR was compared to 571 industry peers in the Biotechnology industry. PHAR has only an average score on both its financial health and profitability. While showing a medium growth rate, PHAR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year PHAR has reported negative net income.
PHAR had a positive operating cash flow in the past year.
Of the past 5 years PHAR 4 years were profitable.
PHAR had a positive operating cash flow in 4 of the past 5 years.
PHAR Yearly Net Income VS EBIT VS OCF VS FCFPHAR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

1.2 Ratios

PHAR's Return On Assets of -4.19% is amongst the best of the industry. PHAR outperforms 89.88% of its industry peers.
PHAR has a better Return On Equity (-7.89%) than 90.76% of its industry peers.
Industry RankSector Rank
ROA -4.19%
ROE -7.89%
ROIC N/A
ROA(3y)1.65%
ROA(5y)5.8%
ROE(3y)3.38%
ROE(5y)12.69%
ROIC(3y)N/A
ROIC(5y)N/A
PHAR Yearly ROA, ROE, ROICPHAR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

1.3 Margins

With an excellent Gross Margin value of 89.39%, PHAR belongs to the best of the industry, outperforming 92.54% of the companies in the same industry.
In the last couple of years the Gross Margin of PHAR has remained more or less at the same level.
PHAR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y1.43%
PHAR Yearly Profit, Operating, Gross MarginsPHAR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

4

2. Health

2.1 Basic Checks

PHAR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PHAR has been increased compared to 1 year ago.
Compared to 5 years ago, PHAR has more shares outstanding
Compared to 1 year ago, PHAR has an improved debt to assets ratio.
PHAR Yearly Shares OutstandingPHAR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
PHAR Yearly Total Debt VS Total AssetsPHAR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 2.05 indicates that PHAR is not a great score, but indicates only limited risk for bankruptcy at the moment.
PHAR has a Altman-Z score of 2.05. This is in the better half of the industry: PHAR outperforms 71.23% of its industry peers.
PHAR has a Debt/Equity ratio of 0.53. This is a neutral value indicating PHAR is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.53, PHAR is doing worse than 75.84% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF N/A
Altman-Z 2.05
ROIC/WACCN/A
WACC6.78%
PHAR Yearly LT Debt VS Equity VS FCFPHAR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 3.53 indicates that PHAR has no problem at all paying its short term obligations.
PHAR has a Current ratio of 3.53. This is comparable to the rest of the industry: PHAR outperforms 41.74% of its industry peers.
PHAR has a Quick Ratio of 2.76. This indicates that PHAR is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.76, PHAR is not doing good in the industry: 66.25% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.53
Quick Ratio 2.76
PHAR Yearly Current Assets VS Current LiabilitesPHAR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

PHAR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.12%.
The Revenue has grown by 30.64% in the past year. This is a very strong growth!
Measured over the past years, PHAR shows a quite strong growth in Revenue. The Revenue has been growing by 11.35% on average per year.
EPS 1Y (TTM)-3.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-140%
Revenue 1Y (TTM)30.64%
Revenue growth 3Y4.96%
Revenue growth 5Y11.35%
Sales Q2Q%12.28%

3.2 Future

PHAR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.00% yearly.
Based on estimates for the next years, PHAR will show a quite strong growth in Revenue. The Revenue will grow by 9.98% on average per year.
EPS Next Y0.22%
EPS Next 2Y6.35%
EPS Next 3Y30.24%
EPS Next 5Y41%
Revenue Next Year18.78%
Revenue Next 2Y13.9%
Revenue Next 3Y12.49%
Revenue Next 5Y9.98%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PHAR Yearly Revenue VS EstimatesPHAR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 100M 200M 300M 400M
PHAR Yearly EPS VS EstimatesPHAR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5 1 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHAR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHAR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHAR Price Earnings VS Forward Price EarningsPHAR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

92.90% of the companies in the same industry are more expensive than PHAR, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 266.61
PHAR Per share dataPHAR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

PHAR's earnings are expected to grow with 30.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.35%
EPS Next 3Y30.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PHAR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHARMING GROUP NV - ADR

NASDAQ:PHAR (2/21/2025, 8:00:01 PM)

8.86

-0.09 (-1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-24 2024-10-24/bmo
Earnings (Next)03-13 2025-03-13/amc
Inst Owners15.1%
Inst Owner Change-100%
Ins Owners1.49%
Ins Owner ChangeN/A
Market Cap601.02M
Analysts86.67
Price Target15.73 (77.54%)
Short Float %0.01%
Short Ratio1.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-87.38%
Min EPS beat(2)-197.09%
Max EPS beat(2)22.33%
EPS beat(4)1
Avg EPS beat(4)-169.28%
Min EPS beat(4)-363.52%
Max EPS beat(4)22.33%
EPS beat(8)3
Avg EPS beat(8)-130.32%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.45%
Min Revenue beat(2)-5.54%
Max Revenue beat(2)-3.36%
Revenue beat(4)1
Avg Revenue beat(4)-5.41%
Min Revenue beat(4)-21.13%
Max Revenue beat(4)8.39%
Revenue beat(8)3
Avg Revenue beat(8)-5.11%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.47%
PT rev (3m)9.33%
EPS NQ rev (1m)-33.3%
EPS NQ rev (3m)-33.3%
EPS NY rev (1m)-45.27%
EPS NY rev (3m)-45.27%
Revenue NQ rev (1m)-1.07%
Revenue NQ rev (3m)-1.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.1
P/FCF N/A
P/OCF 1332.64
P/B 2.66
P/tB 3.79
EV/EBITDA 266.61
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.01
OCFY0.08%
SpS4.21
BVpS3.33
TBVpS2.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.19%
ROE -7.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.39%
FCFM N/A
ROA(3y)1.65%
ROA(5y)5.8%
ROE(3y)3.38%
ROE(5y)12.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y1.43%
F-Score6
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF N/A
Debt/EBITDA 71.79
Cap/Depr 6.22%
Cap/Sales 0.35%
Interest Coverage N/A
Cash Conversion 27.01%
Profit Quality N/A
Current Ratio 3.53
Quick Ratio 2.76
Altman-Z 2.05
F-Score6
WACC6.78%
ROIC/WACCN/A
Cap/Depr(3y)36.48%
Cap/Depr(5y)146.44%
Cap/Sales(3y)3.32%
Cap/Sales(5y)6.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-140%
EPS Next Y0.22%
EPS Next 2Y6.35%
EPS Next 3Y30.24%
EPS Next 5Y41%
Revenue 1Y (TTM)30.64%
Revenue growth 3Y4.96%
Revenue growth 5Y11.35%
Sales Q2Q%12.28%
Revenue Next Year18.78%
Revenue Next 2Y13.9%
Revenue Next 3Y12.49%
Revenue Next 5Y9.98%
EBIT growth 1Y62.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year82.14%
EBIT Next 3Y94.6%
EBIT Next 5Y49.92%
FCF growth 1Y-102.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-98.64%
OCF growth 3YN/A
OCF growth 5YN/A